CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0173 (clinicaltrials.gov NCT No: NCT01779791)
Title:An Open-label, Multicenter, Single-arm, Phase 2 Study of PCI-32765 (ibrutinib) in
Subjects with Refractory Follicular Lymphoma
Principal Investigator:Nathan Fowler
Treatment Agent:PCI-32765
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if ibrutinib can help to
control follicular lymphoma. The safety of this drug will also be studied.

Ibrutinib is designed to stop a protein from working in the cells, which may
cause the cancer cells to die or stop growing.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:PCI-32765
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Janssen Research & Development
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nathan Fowler
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults